ReviewCancers2023
A Global Perspective on Gastric Cancer Screening: Which Concepts Are Feasible, and When?
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06316882 (ROGCAS - Retrospective Observational Gastric Cancer Study), which is not on this map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ROGCAS - Retrospective Observational Gastric Cancer Study
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Upper gastrointestinal endoscopic screening uptake and associated factors in East Asia: a systematic review and meta-analysis.Frontiers in public health · 2026Pooled it
- Effectiveness of Gastric Cancer Endoscopic Screening in Intermediate-Risk Countries-A Systematic Review and Meta-Analysis.United European gastroenterology journal · 2025Pooled it
- Assessing the impact of metabolomic markers on gastric cancer risk: a two-sample Mendelian randomization study.Korean journal of family medicine · 2026Article
- Serum Protein Profiling of Patients at Risk to Develop Gastric Disease Based on a DSC Test.International journal of molecular sciences · 2026Article
- Review
- The evolving role of OMICS in gastrointestinal tumor biology and clinical practice.Molecular cancer · 2026Review
- Gastric intestinal metaplasia: Management and surveillance strategies.World journal of gastrointestinal pathophysiology · 2026Review
- Article
- Mechanistic evaluation of NSC 57774 as a SHP2 inhibitor in gastric cancer: Multi-pathway signaling modulation in vitro.PloS one · 2026Article
- Molecular characteristics andFrontiers in oncology · 2026Article
- Global stomach cancer burden from high-sodium diet and smoking: 1990-2021 findings & 2040 projections.Frontiers in oncology · 2026Review
- Rethinking gastric carcinogenesis: a multiscale ecological model of risk beyondFrontiers in microbiology · 2026Review
- CircRNA CeRNA networks in gastric cancer highlight FAP/FNDC1 as potential prognostic and therapeutic targets.Discover oncology · 2025Article
- Soluble TIM-3 and galectin-9 predict survival in gastric and gastroesophageal junction cancer.iScience · 2025Article
- Hospital spending for cancers in Hunan, China during 2017 and 2019.BMC public health · 2025Article
- ATR-CHK1 Axis Inhibitors in Gastric Cancer Treatment.International journal of molecular sciences · 2025Review
- Early-onset gastrointestinal cancers: comprehensive review and future directions.The British journal of surgery · 2025Review
- Validation of the ABC Method for Gastric Cancer Risk Stratification Across Helicobacter pylori Infections With Diverse CagA Status and Subtypes in Brazil.Cancer medicine · 2025Article
- Article
- Temporal trends, disease burden and attributable risk factors of stomach and colorectal cancers among 31 countries and territories in Western Pacific region, 2000Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) remains the fifth most common cancer and the third most common cause of cancer-related death globally. In 2022, GC fell into the scope of the updated EU recommendations for targeted cancer screening. Given the growing awareness of the GC burden, we aimed to review the existing screening strategies for GC in high-risk regions and discuss potentially applicable modalities in countries with low-to-intermediate incidence.
methodsThe references for this Review article were identified through searches of PubMed with the search terms "gastric cancer", "stomach cancer", "Helicobacter pylori", and "screening" over the period from 1995 until August 2022.
resultsAs
conclusionsGiven the significant variations in GC incidence and healthcare resources around the globe, screening strategies for GC should be adjusted to the actual conditions in each region. While several proven tools exist for accurate GC diagnosis, a universal modality for the screening of GC populations remains elusive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.